CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Short Interest Up 87.5% in December

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) was the target of a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 6,000 shares, a growth of 87.5% from the December 15th total of 3,200 shares. Based on an average daily volume of 14,500 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.1% of the shares of the company are sold short.

Hedge Funds Weigh In On CollPlant Biotechnologies

A hedge fund recently bought a new stake in CollPlant Biotechnologies stock. Benjamin Edwards Inc. purchased a new position in CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 23,810 shares of the company’s stock, valued at approximately $112,000. Benjamin Edwards Inc. owned 0.21% of CollPlant Biotechnologies as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 21.69% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on CLGN shares. HC Wainwright reiterated a “buy” rating and set a $11.00 price objective on shares of CollPlant Biotechnologies in a research report on Friday, November 29th. D. Boral Capital restated a “buy” rating and issued a $14.00 price target on shares of CollPlant Biotechnologies in a research note on Wednesday, November 27th.

CollPlant Biotechnologies Stock Performance

Shares of CLGN stock traded up $0.16 during trading on Thursday, hitting $4.14. The company had a trading volume of 674 shares, compared to its average volume of 6,837. The firm has a market capitalization of $47.35 million, a P/E ratio of -2.69 and a beta of 0.63. CollPlant Biotechnologies has a one year low of $3.24 and a one year high of $6.75. The stock’s 50-day moving average price is $3.98 and its 200 day moving average price is $4.45.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.